Published in Clin Cancer Res on January 15, 2005
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology (2009) 1.32
Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy. Int J Cell Biol (2013) 1.04
Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma. J Proteome Res (2009) 1.04
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene (2015) 1.00
Dickkopfs and Wnt/β-catenin signalling in liver cancer. World J Clin Oncol (2011) 0.94
Cadherin-17 induces tumorigenesis and lymphatic metastasis in gastric cancer through activation of NFκB signaling pathway. Cancer Biol Ther (2013) 0.89
Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences. World J Gastroenterol (2010) 0.86
Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma. PLoS One (2013) 0.84
MicroRNA-375 targets the 3-phosphoinositide-dependent protein kinase-1 gene in pancreatic carcinoma. Oncol Lett (2013) 0.82
Targeting cadherin-17 inactivates Ras/Raf/MEK/ERK signaling and inhibits cell proliferation in gastric cancer. PLoS One (2014) 0.82
Alternative splicing and its impact as a cancer diagnostic marker. Genomics Inform (2012) 0.80
Knockdown of Li-cadherin increases metastatic behaviors of LoVo cells. J Cancer Res Clin Oncol (2010) 0.80
Correlation analysis of liver tumor-associated genes with liver regeneration. World J Gastroenterol (2007) 0.79
Effective gene trapping mediated by Sleeping Beauty transposon. PLoS One (2012) 0.79
Splice variants of zinc finger protein 695 mRNA associated to ovarian cancer. J Ovarian Res (2013) 0.76
Possible roles of LI-Cadherin in the formation and maintenance of the intestinal epithelial barrier. Tissue Barriers (2013) 0.76
Involvement of liver-intestine cadherin in cancer progression. Med Mol Morphol (2013) 0.76
Novel strategies for gene trapping and insertional mutagenesis mediated by Sleeping Beauty transposon. Mob Genet Elements (2013) 0.75
Alternatively spliced isoforms encoded by cadherin genes from C. elegansgenome. Bioinformation (2007) 0.75
Single nucleotide polymorphisms in the CDH17 gene of colorectal carcinoma. World J Gastroenterol (2012) 0.75
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 7.48
Gene expression patterns in human liver cancers. Mol Biol Cell (2002) 6.93
Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell (2008) 6.48
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery (2011) 4.40
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int (2008) 4.16
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience. Ann Surg (2013) 3.11
Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet (2006) 2.96
Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology (2006) 2.78
Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg (2006) 2.59
Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A (2007) 2.56
Hematopoietic chimerism in liver transplantation patients and hematopoietic stem/progenitor cells in adult human liver. Hepatology (2012) 2.47
Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res (2006) 2.32
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res (2008) 2.29
11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective. J Nucl Med (2013) 2.29
Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol (2005) 2.19
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol (2007) 2.06
Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg (2011) 2.05
Identification of local and circulating cancer stem cells in human liver cancer. Hepatology (2008) 2.02
Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg (2004) 1.99
Liver resection using a saline-linked radiofrequency dissecting sealer for transection of the liver. J Am Coll Surg (2005) 1.98
MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun (2010) 1.92
The national program for deceased organ donation in China. Transplantation (2013) 1.83
High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience. Ann Surg (2011) 1.79
Prevention of pancreatic anastomotic leakage after pancreaticoduodenectomy. Am J Surg (2002) 1.77
Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases--activation of cell invasion and migration pathways. Liver Transpl (2007) 1.69
microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol (2010) 1.69
Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology (2010) 1.66
Comparison of early endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography in the management of acute biliary pancreatitis: a prospective randomized study. Clin Gastroenterol Hepatol (2005) 1.66
A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg (2007) 1.63
Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transpl (2007) 1.58
Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One (2011) 1.56
Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB (Oxford) (2011) 1.56
Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim Biophys Acta (2009) 1.55
Working up donors for high-urgency and elective adult-to-adult live donor liver transplantation. Liver Transpl (2007) 1.54
External drainage of pancreatic duct with a stent to reduce leakage rate of pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial. Ann Surg (2007) 1.54
Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol (2005) 1.53
Silver nanoparticles inhibit hepatitis B virus replication. Antivir Ther (2008) 1.53
Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Ann Surg (2013) 1.51
Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open (2012) 1.50
Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation. Liver Transpl (2012) 1.49
Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer (2009) 1.49
Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation. Liver Int (2008) 1.46
Long-term biological consequences of donor right hepatectomy including the middle hepatic vein in adult-to-adult live donor liver transplantation. Liver Transpl (2006) 1.46
Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg (2002) 1.45
Paired donor interchange to avoid ABO-incompatible living donor liver transplantation. Liver Transpl (2010) 1.45
Reduced expression of chemokine receptors on peripheral blood lymphocytes in patients with hepatocellular carcinoma. Am J Gastroenterol (2004) 1.45
Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology (2008) 1.44
Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol (2004) 1.42
Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol (2005) 1.41
Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res (2005) 1.41
DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. J Biol Chem (2011) 1.40
Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics (2007) 1.39
Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg (2007) 1.38
TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Res (2006) 1.35
Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase. Cancer Res (2002) 1.35
Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. Mol Cell Biol (2006) 1.34
Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology (2010) 1.34
Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology (2009) 1.32
Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res (2005) 1.32
High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol (2007) 1.31
FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res (2005) 1.29
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol (2007) 1.28
Kidney claudin-19: localization in distal tubules and collecting ducts and dysregulation in polycystic renal disease. FEBS Lett (2006) 1.27
Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg (2003) 1.27
Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limiting. PLoS One (2011) 1.26
Applicability of intraoperative parathyroid hormone assay during thyroidectomy. Ann Surg (2002) 1.26
Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res (2006) 1.25
Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opin Ther Targets (2010) 1.24
Lessons learned from one hundred right lobe living donor liver transplants. Ann Surg (2004) 1.24
Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg (2002) 1.23
Liver transplantation for acute-on-chronic liver failure. Hepatol Int (2009) 1.23
DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol Cell Biol (2004) 1.22
Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology (2006) 1.20
Toward current standards of donor right hepatectomy for adult-to-adult live donor liver transplantation through the experience of 200 cases. Ann Surg (2007) 1.19
Estimating liver weight of adults by body weight and gender. World J Gastroenterol (2006) 1.17
An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin Cancer Res (2009) 1.16
Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev Res (Phila) (2012) 1.16
Risk factors for biliary complications after liver transplantation. Arch Surg (2004) 1.16
Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clin Cancer Res (2005) 1.15
Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res (2005) 1.15
Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res (2010) 1.15
Increasing the recipient benefit/donor risk ratio by lowering the graft size requirement for living donor liver transplantation. Liver Transpl (2012) 1.14
Expression of hepatocyte-like phenotypes in bone marrow stromal cells after HGF induction. Biochem Biophys Res Commun (2004) 1.13
THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. Oncogene (2005) 1.12